The long-running and deeply unsettling debate over the safety of paracetamol during pregnancy has, for now, been decisively settled. A major new review published in The Lancet Obstetrics, Gynaecology & Women’s Health confirms what major medical organizations have consistently maintained: paracetamol is safe to use during pregnancy and does not increase the risk of autism, ADHD, or developmental issues in children. This finding arrives not a moment too soon, given the unnecessary anxiety stoked by unsubstantiated claims – most notably, those made by former US President Donald Trump and his administration last year.
- Paracetamol is Safe: The comprehensive review of 43 studies involving hundreds of thousands of women provides strong evidence against any link between paracetamol use during pregnancy and neurodevelopmental disorders.
- US Stance Remains Cautious: Despite the robust findings, US health officials continue to express concern, highlighting a divergence in medical opinion.
- Reassurance for Expectant Mothers: Experts emphasize that pregnant women should feel reassured about using paracetamol as directed for pain or fever, as avoiding treatment can pose greater risks.
The controversy ignited in September 2025 when President Trump publicly linked paracetamol (known as acetaminophen in the US) to autism, prompting his administration to advise against its use during pregnancy. This claim, amplified by Health Secretary Robert F. Kennedy Jr.’s focus on rising autism rates, caused widespread confusion and alarm. The source of this concern appeared to stem from a smaller review led by Dr. Andrew Baccarelli at Harvard, which suggested a possible association with heavy or prolonged use. However, that review was quickly criticized for methodological weaknesses and reliance on observational data.
This latest research, however, represents a “gold-standard” analysis. Researchers meticulously examined high-quality studies, crucially focusing on sibling comparisons – meaning they compared pregnancies within the same family where one child was exposed to paracetamol and another wasn’t. This approach effectively controls for genetic and environmental factors, strengthening the validity of the findings. Professor Asma Khalil, lead author of the study, emphasized the clarity of the results: “There was no association, there’s no evidence that paracetamol increases the risk of autism.”
The importance of this reassurance cannot be overstated. Untreated fever or pain during pregnancy carries its own risks – miscarriage, premature birth, and developmental problems in the baby. Paracetamol remains the recommended first-line treatment precisely because it’s considered the safest option. The BBC reports that medical experts not involved in the research have welcomed the study, hoping it will alleviate unnecessary stress for expectant mothers.
The Forward Look
While this review should largely quell the debate, the lingering caution from US health officials signals a potential for continued divergence in guidance. The FDA’s statement acknowledging “many experts” still harbor concerns, despite stating no causal link has been established, suggests a reluctance to fully retract the earlier warnings. Expect continued scrutiny of this issue within the US, potentially leading to further research funded by the NIH. More importantly, this episode underscores the dangerous impact of politicizing scientific findings. The swift and decisive response from the medical community, culminating in this robust review, was necessary to counteract misinformation. Going forward, a greater emphasis on transparent, evidence-based communication from public health authorities will be crucial to maintaining public trust – particularly when dealing with sensitive issues like maternal health. The question now is whether the US will align with the global consensus, or continue to operate under a cloud of unsubstantiated anxieties.
Keep reading
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.